Can a clinic keep compounded peptides in office stock? 503A and 503B checks

01

Office stock describes inventory, not regulatory status

Office stock generally refers to drug supply a clinic or health care facility keeps for administration or dispensing-related workflows rather than a container compounded only after a named patient’s prescription arrives. The phrase alone does not identify who made the drug, which federal section is being relied on, or whether state law permits the transaction.

Ask the clinic whether the product came from a state-licensed 503A pharmacy, an FDA-registered 503B outsourcing facility, a conventional manufacturer, or compounding performed by a practitioner. Then obtain the exact legal name and physical address of the facility that produced the lot. A distributor, clinic brand, or parent company is not a substitute.

Do not assume that office administration makes a product FDA-approved. FDA states that compounded drugs are not approved and do not undergo the agency’s premarket review for safety, effectiveness, and quality.

02

Section 503A is built around an identified patient

The federal statute for section 503A describes compounding for an identified individual patient based on a valid prescription order or an approved notation that a compounded product is necessary. It also allows limited anticipatory compounding before receipt of the patient’s prescription when tied to a history of valid orders generated within established relationships described in the law.

That is not a general federal permission to manufacture unlimited clinic inventory. Whether a particular pharmacy-to-clinic transfer is allowed can also depend on state law, board interpretations, who administers or dispenses the drug, and other facts. An article cannot resolve those legal questions for every jurisdiction.

For a patient, the useful verification questions are concrete: Was the container labeled for the patient? When did the pharmacy receive the prescription? Was the product transferred to the clinic? Which state licenses cover the pharmacy and clinic? The answers should be documented rather than inferred from a “503A” badge.

03

Section 503B supports a different office-stock pathway

FDA says a 503B outsourcing facility is engaged in compounding sterile drugs, elects to register, and must satisfy section 503B requirements. Such facilities may or may not obtain prescriptions for identified individual patients. This structure is why health care facilities may look to 503B suppliers for certain office-stock needs.

Outsourcing facilities are subject to current good manufacturing practice requirements, risk-based FDA inspection, adverse-event reporting, registration, and product reporting conditions. Their compounded drugs remain exempt from approval requirements only when applicable conditions are met; the individual products are not FDA-approved.

The facility’s public record should be checked by exact location. FDA emphasizes that registration and inspections are facility-specific, even when multiple sites share ownership. A corporate logo cannot transfer one location’s registration or inspection history to another.

04

Registration and inspection require careful reading

FDA’s registered-outsourcing-facility table shows the most recent registration, inspection information, whether a Form 483 was issued, recall information, action based on the last inspection, and whether the facility intends to compound sterile drugs from bulk substances. The table was updated July 28, 2026 when this article was researched.

Registration means FDA received a complete registration submission; FDA explicitly says it does not mean the facility makes FDA-approved drugs or is compliant with every requirement. Likewise, a Form 483 lists inspection observations and is not a final agency determination. An open action, warning letter, recall, or close-out record must be read in context.

Record the facility’s exact address, inspection date, action status, and the date you checked. Do not describe an inspection as a permanent certificate of safety. FDA calls it a snapshot in time and says conditions can change.

05

The product and ingredient still need separate checks

A facility’s status does not establish that every bulk substance is eligible or that every drug qualifies for the statutory exemptions. Section 503A and 503B have different bulk-substance, essentially-a-copy, withdrawn-drug, and other conditions. Peptide ingredients that FDA identifies as ineligible or presenting significant safety concerns do not become acceptable merely because a registered facility appears in the transaction.

Search the 503B outsourcing-facility product-report database for the exact facility, ingredient, dosage form, route, and reporting period. Product reports can show what a facility reported compounding, but they are not approval records, proof of current availability, or a batch release certificate.

Match the clinic’s vial to the label, lot, compounder address, and product report. Ask whether the clinic received it directly from the compounder and how it was stored. If the product name, facility, or lot cannot be identified, the office-stock pathway remains unverified.

06

Questions to ask before a clinic administers office stock

Ask the clinic to name the drug, route, concentration, total amount, compounder, facility address, lot, beyond-use date, storage conditions, and whether the supply was patient-specific or office stock. Confirm who prescribed or ordered it and which licensed professional will administer it. These are research questions, not a request for a treatment recommendation.

For a claimed 503B source, verify the exact facility in FDA’s current table, review inspection and recall links, and search its product reports. For a claimed 503A patient-specific product, verify the dispensing pharmacy and prescription pathway with the relevant state records. Ask which state law the clinic relies on for possession and administration.

Warning signs include a clinic refusing to name the compounder, using “FDA-registered” as if it meant FDA-approved, showing records for a different facility, offering a research-use vial for patient administration, or lacking traceable lot and BUD information. Treatment suitability belongs with a licensed clinician; regulatory verification cannot determine whether a drug is right for a person.

• →Patient-specific or office stock
• →Exact compounder and facility address
• →Current registration, inspection, and state licenses
• →Product report, ingredient eligibility, and lot
• →Label, BUD, storage, prescriber, and administrator